CA3233139A1 - Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use - Google Patents

Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use Download PDF

Info

Publication number
CA3233139A1
CA3233139A1 CA3233139A CA3233139A CA3233139A1 CA 3233139 A1 CA3233139 A1 CA 3233139A1 CA 3233139 A CA3233139 A CA 3233139A CA 3233139 A CA3233139 A CA 3233139A CA 3233139 A1 CA3233139 A1 CA 3233139A1
Authority
CA
Canada
Prior art keywords
microparticles
polymer
pharmaceutical formulation
poly
tacrolimus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233139A
Other languages
English (en)
French (fr)
Inventor
Evangelos Karavas
Efthymios Koutris
Lida Kalantzi
Sotiria CHATIDOU
Nikos Lemonakis
Anna Papadaki
Vincent Brieudes
Artemis Kalezi
Athanasios Katsenis
Katerina KOTTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmathen SA
Original Assignee
Pharmathen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GR20210100639A external-priority patent/GR1010308B/el
Priority claimed from GB2116138.5A external-priority patent/GB2612779A/en
Application filed by Pharmathen SA filed Critical Pharmathen SA
Publication of CA3233139A1 publication Critical patent/CA3233139A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3233139A 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use Pending CA3233139A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GR20210100639A GR1010308B (el) 2021-09-27 2021-09-27 Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου
GR20210100639 2021-09-27
GB2116138.5A GB2612779A (en) 2021-11-10 2021-11-10 Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
GB2116138.5 2021-11-10
PCT/EP2022/025445 WO2023046321A1 (en) 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Publications (1)

Publication Number Publication Date
CA3233139A1 true CA3233139A1 (en) 2023-03-30

Family

ID=83902713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233139A Pending CA3233139A1 (en) 2021-09-27 2022-09-27 Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use

Country Status (10)

Country Link
US (1) US20250319028A1 (https=)
EP (1) EP4440550A1 (https=)
JP (1) JP2024536879A (https=)
KR (1) KR20240060874A (https=)
AU (1) AU2022351126A1 (https=)
CA (1) CA3233139A1 (https=)
CO (1) CO2024005380A2 (https=)
MX (1) MX2024003886A (https=)
WO (1) WO2023046321A1 (https=)
ZA (1) ZA202403104B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120000593B (zh) * 2024-12-27 2026-03-20 广东药科大学 一种他克莫司微晶及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
MX2007011494A (es) 2005-03-17 2007-12-06 Elan Pharma Int Ltd Composiciones inyectables de compuestos inmunosupresores nanoparticulados.
WO2017173534A1 (en) * 2016-04-05 2017-10-12 The Hospital For Sick Children System for delivery of fk506 for enhancing nerve regeneration

Also Published As

Publication number Publication date
CO2024005380A2 (es) 2024-05-30
MX2024003886A (es) 2024-07-10
WO2023046321A1 (en) 2023-03-30
WO2023046321A8 (en) 2024-05-30
AU2022351126A1 (en) 2024-05-09
EP4440550A1 (en) 2024-10-09
KR20240060874A (ko) 2024-05-08
JP2024536879A (ja) 2024-10-08
US20250319028A1 (en) 2025-10-16
ZA202403104B (en) 2025-01-29

Similar Documents

Publication Publication Date Title
RU2449785C2 (ru) Мицеллярная композиция амфифильного блок-сополимера, содержащая таксан, и способ ее получения
Wischke et al. Development of PLGA-based injectable delivery systems for hydrophobic fenretinide
CN1429120A (zh) 稳定的聚合胶束型药物组合物和制备它的方法
US9795562B2 (en) Method for stabilizing amphiphilic block copolymer micelle composition containing poorly water-soluble drug
KR102223812B1 (ko) 난용성 약물 서방출용 미립구의 제조방법
KR101930588B1 (ko) 마이크로입자 중에 소마토스타틴 유도체를 포함하는 연장-방출 조성물
JP2016527308A (ja) エンテカビル微小球及びこれを含む非経口投与用医薬組成物
KR20210054660A (ko) 초기 방출 제어가 가능한 서방출성 미립구 및 이의 제조 방법
CN103893129B (zh) 帕潘立酮缓释微球及其注射剂和该缓释微球的制备方法
US20250319028A1 (en) Pharmaceutical formulation comprising tacrolimus, method for the preparation thereof and use
CN103948911B (zh) 一种棘白菌素类抗真菌药物缓释微球制剂及其制备方法
AU2007263004A1 (en) Sustained release formulations of aromatase inhibitors
GB2612779A (en) Pharmaceutical formulation comprising Tacrolimus, method for the preparation thereof and use
ZA200502858B (en) Controlled releases system containing temozolomide
CN118043036A (zh) 包含他克莫司的药物制剂、其制备方法和用途
HK40104581A (zh) 包含他克莫司的药物制剂、其制备方法和用途
US20240216280A1 (en) Microsphere formulations comprising nalmefene andmethods for making and using the same
US20190117573A1 (en) Composition and method of preparation of risperidone extended release preparation
CN104825399A (zh) 包载康普瑞丁磷酸二钠的反胶束-微球缓释制剂及其制备方法
CN1927183B (zh) 抗肿瘤药物表阿霉素缓释微球制剂及制备方法
CN1969820A (zh) 抗癌药物组合物
CN118267362A (zh) 一种爱地那非长效缓释注射剂及其制备方法和用途
CN1687494A (zh) 卡氮芥的超细纤维剂型的制备方法
EP3372224A1 (en) New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
CN101002729A (zh) 含血管抑制剂的抗癌缓释剂

Legal Events

Date Code Title Description
R15 Change to inventor requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R15-R108 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUEST RECEIVED

Effective date: 20240802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250711

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250711

R16 Change to inventor recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R16-R110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRECT INVENTOR REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260330

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260330

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260330